Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations
This article was originally published in The Gray Sheet
Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.
You may also be interested in...
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
Pursuit of cardiovascular indications for Advanced Tissue Sciences' Dermagraft fibroblast tissue repair technology is likely to hinge upon finding a joint venture partner for the product, according to the La Jolla, California-based company.
Smith & Nephew will employ its 300-person direct sales force to promote an expanded indication for the Exogen 2000 low-intensity pulsed ultrasound device for treatment of non-union bone fractures, a market valued at roughly $110 mil.